
    
      A randomized, open label, 3-period crossover study in healthy subjects. The primary objective
      of this study is to determine the relative bioavailability of GSK1278863A after single oral
      doses of 100mg GSK1278863A tablets with particle sizes of 13, 29, or 41 micrometers (um) in
      healthy subjects.
    
  